Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

Documenti analoghi

• MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
  di: Lambert, Juliette, et al.
  Pubblicazione: (2014)
• Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
  di: Renneville, Aline, et al.
  Pubblicazione: (2014)
• Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
  di: Lesieur, Auriane, et al.
  Pubblicazione: (2020)
• Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
  di: Ferret, Yann, et al.
  Pubblicazione: (2018)
• Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria
  di: Itzykson, Raphael, et al.
  Pubblicazione: (2011)